Unlock stock picks and a broker-level newsfeed that powers Wall Street.

TSX April 2025 Spotlight: Promising Penny Stocks To Consider

In This Article:

As the Canadian market navigates through trade uncertainty and inflation concerns, investors are keenly observing how newly announced tariffs might impact economic growth. Amidst this backdrop, penny stocks—often representing smaller or newer companies—continue to capture attention for their potential value and growth opportunities. Despite being a somewhat outdated term, these stocks can offer affordability paired with financial strength, making them an intriguing option for those looking to explore promising investment avenues in today's market landscape.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

Westbridge Renewable Energy (TSXV:WEB)

CA$0.71

CA$68.78M

★★★★★★

Haivision Systems (TSX:HAI)

CA$4.32

CA$121.88M

★★★★★☆

NTG Clarity Networks (TSXV:NCI)

CA$1.82

CA$78.83M

★★★★★☆

Intermap Technologies (TSX:IMP)

CA$1.87

CA$109.04M

★★★★☆☆

Orezone Gold (TSX:ORE)

CA$0.92

CA$484.66M

★★★★★☆

Dynacor Group (TSX:DNG)

CA$4.70

CA$201.34M

★★★★★★

PetroTal (TSX:TAL)

CA$0.69

CA$613.7M

★★★★★☆

McCoy Global (TSX:MCB)

CA$3.12

CA$88.33M

★★★★★★

Findev (TSXV:FDI)

CA$0.48

CA$13.75M

★★★★★★

BluMetric Environmental (TSXV:BLM)

CA$1.17

CA$42.83M

★★★★★★

Click here to see the full list of 923 stocks from our TSX Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Cronos Group

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cronos Group Inc. is a cannabinoid company involved in the cultivation, production, distribution, and marketing of cannabis products across Canada, Israel, and internationally with a market cap of CA$979.28 million.

Operations: The company's revenue primarily comes from the cultivation, manufacture, and marketing of cannabis and cannabis-derived products, totaling $117.62 million.

Market Cap: CA$979.28M

Cronos Group Inc., with a market cap of CA$979.28 million, has recently turned profitable, reporting a net income of US$41.08 million for 2024 compared to a significant loss the previous year. The company’s revenue grew to US$117.62 million, driven by its cannabis operations across multiple regions. Despite low return on equity and past earnings volatility due to one-off losses, Cronos remains debt-free with strong asset coverage over liabilities. The recent appointment of Anna Shlimak as CFO could enhance strategic initiatives aimed at long-term growth and operational efficiency within the cannabis sector.

Waiting for permission
Allow microphone access to enable voice search

Try again.